Top ▲

NET

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 926

Nomenclature: NET

Systematic Nomenclature: SLC6A2

Family: Monoamine transporter subfamily

Contents:

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 12 617 16q12.2 SLC6A2 solute carrier family 6 member 2
Mouse 12 617 8 44.99 cM Slc6a2 solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2
Rat - - 19p11 Slc6a2 solute carrier family 6 member 2
Previous and Unofficial Names Click here for help
NAT1 | NET1 | SLC6A5 | NaCl-dependent norepinephrine transporter | norepinephrine transporter | sodium-dependent noradrenaline transporter | NE transporter | solute carrier family 6 (neurotransmitter transporter), member 2 | solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | solute carrier family 6 (neurotransmitter transporter
Database Links Click here for help
Specialist databases
Bioparadigms SLC Tables SLC6A2 (Hs)
RESOLUTE SLC6A2 (Hs)
Other databases
Alphafold P23975 (Hs), O55192 (Mm)
ChEMBL Target CHEMBL222 (Hs), CHEMBL2370 (Mm)
DrugBank Target P23975 (Hs)
Ensembl Gene ENSG00000103546 (Hs), ENSMUSG00000055368 (Mm), ENSRNOG00000016311 (Rn)
Entrez Gene 6530 (Hs), 20538 (Mm), 83511 (Rn)
Human Protein Atlas ENSG00000103546 (Hs)
KEGG Gene hsa:6530 (Hs), mmu:20538 (Mm), rno:83511 (Rn)
OMIM 163970 (Hs)
Pharos P23975 (Hs)
UniProtKB P23975 (Hs), O55192 (Mm)
Wikipedia SLC6A2 (Hs)
Substrates and Reaction Kinetics Click here for help
Substrate Sp. Property Value Units Standard property Standard value Assay description Assay conditions Comments Reference
(-)-adrenaline Substrate is endogenous in the given species Hs -
(-)-noradrenaline Substrate is endogenous in the given species Hs -
dopamine Substrate is endogenous in the given species Hs -
MPP+ Hs -
methamphetamine Hs -
amphetamine Hs -
Stoichiometry Click here for help
1 noradrenaline: 1 Na+:1 Cl- [8]

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
[3H]mazindol Small molecule or natural product Ligand is labelled Ligand is radioactive Rn Inhibition 9.3 pKd 18
⤷ pKd 9.3 (Kd 5x10-10 M) [18]
protriptyline Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.9 pKd 22
⤷ pKd 8.9 (Kd 1.41x10-9 M) [22]
atomoxetine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.7 pKd 5
⤷ pKd 8.7 (Kd 2.03x10-9 M) [5]
[3H]nisoxetine Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Inhibition 8.4 pKd
⤷ pKd 8.4 (Kd 4x10-9 M)
clomipramine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.4 pKd 22
⤷ pKd 7.4 (Kd 3.8x10-8 M) [22]
nefazodone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 6.4 pKd 5
⤷ pKd 6.4 (Kd 3.6x10-7 M) [5]
Description: Dissociation constant of [3H]- nisoxatine vs. nefazodone.
mazindol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 8.9 pKi
⤷ pKi 8.9 (Ki 1.26x10-9 M)
desipramine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.7 pKi 16
⤷ pKi 8.7 (Ki 2.1x10-9 M) [16]
nisoxetine Small molecule or natural product Hs Inhibition 8.4 pKi
⤷ pKi 8.4 (Ki 3.98x10-9 M)
lofepramine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.3 pKi 22
⤷ pKi 8.3 (Ki 5.4x10-9 M) [22]
duloxetine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.2 pKi 17
⤷ pKi 8.2 (Ki 5.97x10-9 M) [17]
nortriptyline Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.2 pKi 7
⤷ pKi 8.2 (Ki 6.3x10-9 M) [7]
protriptyline Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.2 pKi 13
⤷ pKi 8.2 (Ki 6.8x10-9 M) [13]
H05 Small molecule or natural product Click here for species-specific activity table Rn Inhibition 8.2 pKi 28
⤷ pKi 8.2 (Ki 6.72x10-9 M) [28]
nomifensine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.1 pKi
⤷ pKi 8.1 (Ki 7.94x10-9 M)
reboxetine Small molecule or natural product Approved drug Primary target of this compound Hs Inhibition 8.0 pKi 27
⤷ pKi 8.0 (Ki 1x10-8 M) [27]
maprotiline Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 7.9 pKi 9
⤷ pKi 7.9 (Ki 1.2x10-8 M) [9]
N-desalkylquetiapine Small molecule or natural product Hs Inhibition 7.9 pKi 10
⤷ pKi 7.9 (Ki 1.2x10-8 M) [10]
amoxapine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 7.9 pKi 3
⤷ pKi 7.9 (Ki 1.3x10-8 M) [3]
imipramine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.8 pKi
⤷ pKi 7.8 (Ki 1.6x10-8 M)
mianserin Small molecule or natural product Approved drug Click here for species-specific activity table Rn Inhibition 7.6 pKi 14
⤷ pKi 7.6 (Ki 2.6x10-8 M) [14]
Description: Inhibition of [3H]NE uptake into rat synaptosomes
doxepin Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.5 pKi 3
⤷ pKi 7.5 (Ki 2.9x10-8 M) [3]
dosulepin Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 7.3 pKi 22
⤷ pKi 7.3 (Ki 4.6x10-8 M) [22]
ziprasidone Small molecule or natural product Approved drug Rn Inhibition 7.3 pKi 1
⤷ pKi 7.3 (Ki 4.8x10-8 M) [1]
dexamfetamine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.0 pKi 2
⤷ pKi 7.0 (Ki 1.01x10-7 M) [2]
dexmethylphenidate Small molecule or natural product Approved drug Rn Inhibition 6.6 pKi 11
⤷ pKi 6.6 (Ki 2.7x10-7 M) [11]
Description: Displacement of [3H]nisoxetine from NET in Sprague-Dawley rat cortical tissue.
amitriptyline Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.5 pKi 2
⤷ pKi 6.5 (Ki 3.33x10-7 M) [2]
bupropion Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 6.4 pKi 12
⤷ pKi 6.4 (Ki 4.41x10-7 M) [12]
desvenlafaxine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition <6.2 pKi 6
⤷ pKi <6.2 (Ki >6.5x10-7 M) [6]
quetiapine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 6.0 pKi 10
⤷ pKi 6.0 (Ki 9.27x10-7 M) [10]
trimipramine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 5.6 pKi 22
⤷ pKi 5.6 (Ki 2.45x10-6 M) [22]
solriamfetol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 5.4 pKi 4
⤷ pKi 5.4 (Ki 3.7x10-6 M) [4]
Description: In a radioligand binding assay using HEK293 cells expressing hNET.
sibutramine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 5.3 pKi 3
⤷ pKi 5.3 (Ki 5.619x10-6 M) [3]
tapentadol Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 5.1 pKi 24
⤷ pKi 5.1 (Ki 8.8x10-6 M) [24]
phenelzine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition <5.0 pKi 22
⤷ pKi <5.0 (Ki >1x10-5 M) [22]
citalopram Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition <3.0 pKi 29
⤷ pKi <3.0 (Ki >1x10-3 M) [29]
Description: Inhibition of [3H]dopamine uptake at human NET expressed in COS7 cells.
milnacipran Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 9.1 pIC50 25
⤷ pIC50 9.1 (IC50 7.94x10-10 M) [25]
protriptyline Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.8 pIC50 15
⤷ pIC50 8.8 (IC50 1.7x10-9 M) [15]
Description: Inhibition of [3H]nisoxetine binding to CHO cells expressing hNET.
norzotepine Small molecule or natural product Click here for species-specific activity table Hs Inhibition 8.0 pIC50 20
⤷ pIC50 8.0 (IC50 1.1x10-8 M) [20]
levomilnacipran Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 7.4 pIC50 26
⤷ pIC50 7.4 (IC50 4x10-8 M) [26]
methylphenidate Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 7.2 pIC50
⤷ pIC50 7.2 (IC50 6.1x10-8 M)
zotepine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.2 pIC50 20
⤷ pIC50 7.2 (IC50 7.1x10-8 M) [20]
venlafaxine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 6.3 pIC50 19
⤷ pIC50 6.3 (IC50 5.35x10-7 M) [19]
toludesvenlafaxine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 6.1 pIC50 21
⤷ pIC50 6.1 (IC50 7.63x10-7 M) [21]
solriamfetol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 5.4 pIC50 4
⤷ pIC50 5.4 (IC50 4.4x10-6 M) [4]
Description: In a NE reuptake assay in HEK293 cells expressing hNET.
View species-specific inhibitor tables
Inhibitor Comments
Protriptyline has also been shown to inhibit uptake of 5-HT in platelet rich human plasma [23].
Venlafaxine has a lower IC50 for SERT than for NET, therefore SERT has been tagged as the drug's primary target.
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Orthostatic intolerance
OMIM: 604715

References

Show »

1. Ablordeppey SY, Altundas R, Bricker B, Zhu XY, Kumar EV, Jackson T, Khan A, Roth BL. (2008) Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. Bioorg Med Chem, 16 (15): 7291-301. [PMID:18595716]

2. Arunotayanun W, Dalley JW, Huang XP, Setola V, Treble R, Iversen L, Roth BL, Gibbons S. (2013) An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'. Bioorg Med Chem Lett, 23 (11): 3411-5. [PMID:23602445]

3. Auerbach SS, DrugMatrix® and ToxFX® Coordinator National Toxicology Program. National Toxicology Program: Dept of Health and Human Services. Accessed on 02/05/2014. Modified on 02/05/2014. DrugMatrix, https://ntp.niehs.nih.gov/drugmatrix/index.html

4. Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A. (2018) Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther, 366 (2): 367-376. [PMID:29891587]

5. Carlier PR, Lo MM, Lo PC, Richelson E, Tatsumi M, Reynolds IJ, Sharma TA. (1998) Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg Med Chem Lett, 8 (5): 487-92. [PMID:9871604]

6. Dreyfus N, Myers JK, Badescu VO, de Frutos O, de la Puente ML, Ding C, Filla SA, Fynboe K, Gernert DL, Heinz BA et al.. (2013) Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor. ACS Med Chem Lett, 4 (6): 560-4. [PMID:24900709]

7. Glennon RA, Lee M, Rangisetty JB, Dukat M, Roth BL, Savage JE, McBride A, Rauser L, Hufeisen S, Lee DK. (2000) 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem, 43 (5): 1011-8. [PMID:10715164]

8. Gu HH, Wall S, Rudnick G. (1996) Ion coupling stoichiometry for the norepinephrine transporter in membrane vesicles from stably transfected cells. J Biol Chem, 271 (12): 6911-6. [PMID:8636118]

9. Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, Robichaud AJ, Huselton C, Alfinito P, Bray JA et al.. (2009) Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles. Bioorg Med Chem, 17 (22): 7802-15. [PMID:19836247]

10. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology, 33 (10): 2303-12. [PMID:18059438]

11. Kim DI, Deutsch HM, Ye X, Schweri MM. (2007) Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem, 50 (11): 2718-31. [PMID:17489581]

12. Lapinsky DJ, Aggarwal S, Huang Y, Surratt CK, Lever JR, Foster JD, Vaughan RA. (2009) A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. Bioorg Med Chem, 17 (11): 3770-4. [PMID:19442525]

13. Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR et al.. (2008) cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J Med Chem, 51 (22): 7094-8. [PMID:18983139]

14. Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, Schneider CR. (1984) Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin. J Med Chem, 27 (8): 943-6. [PMID:6747993]

15. Mladenova G, Annedi SC, Ramnauth J, Maddaford SP, Rakhit S, Andrews JS, Zhang D, Porreca F. (2012) First-in-class, dual-action, 3,5-disubstituted indole derivatives having human nitric oxide synthase (nNOS) and norepinephrine reuptake inhibitory (NERI) activity for the treatment of neuropathic pain. J Med Chem, 55 (7): 3488-501. [PMID:22420844]

16. O'Neill DJ, Adedoyin A, Alfinito PD, Bray JA, Cosmi S, Deecher DC, Fensome A, Harrison J, Leventhal L, Mann C et al.. (2010) Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231). J Med Chem, 53 (11): 4511-21. [PMID:20462211]

17. Pechulis AD, Beck JP, Curry MA, Wolf MA, Harms AE, Xi N, Opalka C, Sweet MP, Yang Z, Vellekoop AS et al.. (2012) 4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors. Bioorg Med Chem Lett, 22 (23): 7219-22. [PMID:23084899]

18. Raffel DM, Chen W. (2004) Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol, 370 (1): 9-16. [PMID:15300361]

19. Sabatucci JP, Mahaney PE, Leiter J, Johnston G, Burroughs K, Cosmi S, Zhang Y, Ho D, Deecher DC, Trybulski E. (2010) Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors. Bioorg Med Chem Lett, 20 (9): 2809-12. [PMID:20378347]

20. Shobo M, Kondo Y, Yamada H, Mihara T, Yamamoto N, Katsuoka M, Harada K, Ni K, Matsuoka N. (2010) Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther, 333 (3): 772-81. [PMID:20223878]

21. Subbaiah MAM. (2019) Correction to "Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges". J Med Chem, 62 (21): 10003. [PMID:31617718]

22. Tatsumi M, Groshan K, Blakely RD, Richelson E. (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol, 340 (2-3): 249-58. [PMID:9537821]

23. Trenchard A, Turner P, Pare CM, Hills M. (1975) The effects of protriptyline and clomipramine in vitro on the uptake of 5-hydroxytryptamine and dopamine in human platelet-rich plasma. Psychopharmacologia, 43 (1): 89-93. [PMID:1161997]

24. Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E et al.. (2007) (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther, 323 (1): 265-76. [PMID:17656655]

25. Van Orden LJ, Van Dyke PM, Saito DR, Church TJ, Chang R, Smith JA, Martin WJ, Jaw-Tsai S, Stangeland EL. (2013) A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships. Bioorg Med Chem Lett, 23 (5): 1456-61. [PMID:23347683]

26. Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L et al.. (2008) Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, 18 (11): 3230-5. [PMID:18468895]

27. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A et al.. (2000) Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry, 47 (9): 818-29. [PMID:10812041]

28. Xu X, Wei Y, Guo Q, Zhao S, Liu Z, Xiao T, Liu Y, Qiu Y, Hou Y, Zhang G et al.. (2018) Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression. J Pharmacol Exp Ther, 365 (3): 624-635. [PMID:29615471]

29. Zhang P, Jørgensen TN, Loland CJ, Newman AH. (2013) A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter. Bioorg Med Chem Lett, 23 (1): 323-6. [PMID:23168018]

Contributors

Show »

How to cite this page